JPWO2021122998A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2021122998A5 JPWO2021122998A5 JP2022537736A JP2022537736A JPWO2021122998A5 JP WO2021122998 A5 JPWO2021122998 A5 JP WO2021122998A5 JP 2022537736 A JP2022537736 A JP 2022537736A JP 2022537736 A JP2022537736 A JP 2022537736A JP WO2021122998 A5 JPWO2021122998 A5 JP WO2021122998A5
- Authority
- JP
- Japan
- Prior art keywords
- saponin
- aspects
- residues
- transfection
- acetyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 229930182490 saponin Natural products 0.000 description 17
- 150000007949 saponins Chemical class 0.000 description 17
- 235000017709 saponins Nutrition 0.000 description 17
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 16
- 239000012096 transfection reagent Substances 0.000 description 9
- 238000000034 method Methods 0.000 description 8
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 6
- 238000001890 transfection Methods 0.000 description 5
- 210000004027 cell Anatomy 0.000 description 4
- 150000007523 nucleic acids Chemical class 0.000 description 4
- 239000002502 liposome Substances 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 102000039446 nucleic acids Human genes 0.000 description 3
- 108020004707 nucleic acids Proteins 0.000 description 3
- 229920000642 polymer Polymers 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 240000000254 Agrostemma githago Species 0.000 description 2
- 235000009899 Agrostemma githago Nutrition 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 210000003527 eukaryotic cell Anatomy 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- 125000004430 oxygen atom Chemical group O* 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 1
- 238000013375 chromatographic separation Methods 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 125000002791 glucosyl group Chemical group C1([C@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 239000002105 nanoparticle Substances 0.000 description 1
- 231100000065 noncytotoxic Toxicity 0.000 description 1
- 238000010298 pulverizing process Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
Description
(結論)
AG1856は、RIPをコードするナノプレックスの細胞毒性効果において極めて重要であった。このトランスフェクション増強剤がなければ、細胞毒性効果は観察されなかった。
なお、本発明は、態様として以下の内容を含む。
〔態様1〕
式(I)で表されるサポニン:
〔態様2〕
態様1に記載のサポニンであって、4つのアセチル残基を有することを特徴とする、サポニン。
〔態様3〕
態様2に記載のサポニンであって、それぞれの場合において、1つのアセチル残基が、対応するキノボース残基のC3およびC4位置の酸素原子に結合しており、並びに、対応するグルコース残基のC4およびC6位置の酸素原子に結合していることを特徴とする、サポニン。
〔態様4〕
核酸、脂質、ペプチドおよび/またはタンパク質の細胞へのインビトロ送達における、態様1~3のいずれかに一項に記載のサポニンの使用。
〔態様5〕
態様4に記載の使用であって、細胞が真核生物細胞であることを特徴とする、使用。
〔態様6〕
核酸、脂質、ペプチドおよび/またはタンパク質をヒトまたは動物にインビボ送達することによる治療または診断に用いるための、態様1~3のいずれか一態様に記載のサポニン。
〔態様7〕
態様4若しくは5の使用、または態様6に用いられるサポニンであって、サポニンが、リポソームベースのトランスフェクション試薬およびポリマーベースのトランスフェクション試薬からなる群の中から選択される少なくとも1つのトランスフェクション試薬と組み合わせて適用されることを特徴とする、使用またはサポニン。
〔態様8〕
態様1~3のいずれか一態様に記載のサポニンを含む、トランスフェクション組成物。
〔態様9〕
態様8に記載のトランスフェクション組成物であって、リポソームベースのトランスフェクション試薬及びポリマーベースのトランスフェクション試薬からなる群の中から選択される少なくとも1つのトランスフェクション試薬を更に含むことを特徴とする、トランスフェクション組成物。
〔態様10〕
インビトロトランスフェクションのための方法であって、態様1~3のいずれか一態様に記載のサポニンの存在下で細胞を核酸と一緒にインキュベートする工程を含む、方法。
〔態様11〕
態様10に記載の方法であって、前記細胞が真核細胞であることを特徴とする、方法。
〔態様12〕
態様10または11に記載の方法であって、核酸がナノ粒子の一部を形成することを特徴とする、方法。
〔態様13〕
態様10~12のいずれか一態様に記載の方法であって、サポニンが1μg/mL~50μg/mLの範囲内の濃度で使用されることを特徴とする、方法。
〔態様14〕
態様10~13のいずれか一態様に記載の方法であって、サポニンが、リポソームベースのトランスフェクション試薬およびポリマーベースのトランスフェクション試薬からなる群の中から選択される少なくとも1つのトランスフェクション試薬と組み合わせて使用されることを特徴とする、方法。
〔態様15〕
態様1から3のいずれか一態様に記載のサポニンをAgrostemma githago L.から単離する方法であって、以下の工程:
Agrostemma githago L.の種子を粉砕し、粉砕した種子を有機溶媒により脱脂して、脱脂粉砕種子を得る工程;
前記脱脂粉砕種子を凍結乾燥して種子粉末を得る工程;
前記種子粉末をアルコール溶媒で抽出し、種子抽出物を得る工程;
前記種子抽出物からアルコール溶媒を除去し、乾燥抽出物を得る工程;
前記乾燥抽出物を低濃度有機溶媒に溶解し、抽出物溶液を得る工程;
前記抽出物溶液を少なくとも1つのクロマトグラフィー分離工程に供して、精製されたサポニン溶液を得る工程;及び
前記精製されたサポニン溶液から溶媒を除去し、精製サポニン粉末を得る工程;
を含む、方法。
(Conclusion)
AG1856 was crucial in the cytotoxic effects of nanoplexes encoding RIP. Without this transfection enhancer, no cytotoxic effects were observed.
Note that the present invention includes the following aspects as aspects.
[Aspect 1]
Saponin represented by formula (I):
[Aspect 2]
Saponin according to aspect 1, characterized in that it has four acetyl residues.
[Aspect 3]
Saponin according to aspect 2, in each case one acetyl residue is bonded to the oxygen atoms in the C3 and C4 positions of the corresponding quinobose residue, and in the C4 of the corresponding glucose residue. and a saponin bonded to an oxygen atom at the C6 position.
[Aspect 4]
Use of a saponin according to any one of aspects 1 to 3 in the in vitro delivery of nucleic acids, lipids, peptides and/or proteins to cells.
[Aspect 5]
Use according to aspect 4, characterized in that the cells are eukaryotic cells.
[Aspect 6]
Saponin according to any one of aspects 1 to 3 for use in therapy or diagnosis by in vivo delivery of nucleic acids, lipids, peptides and/or proteins to humans or animals.
[Aspect 7]
A saponin for use in embodiment 4 or 5, or in embodiment 6, wherein the saponin is combined with at least one transfection reagent selected from the group consisting of liposome-based transfection reagents and polymer-based transfection reagents. Use or saponins, characterized in that they are applied in combination.
[Aspect 8]
A transfection composition comprising a saponin according to any one of aspects 1 to 3.
[Aspect 9]
Transfection composition according to aspect 8, characterized in that it further comprises at least one transfection reagent selected from the group consisting of liposome-based transfection reagents and polymer-based transfection reagents. Transfection composition.
[Aspect 10]
A method for in vitro transfection, comprising incubating cells with a nucleic acid in the presence of a saponin according to any one of aspects 1 to 3.
[Aspect 11]
11. The method according to aspect 10, characterized in that said cell is a eukaryotic cell.
[Aspect 12]
12. A method according to aspect 10 or 11, characterized in that the nucleic acid forms part of the nanoparticle.
[Aspect 13]
Method according to any one of aspects 10 to 12, characterized in that the saponin is used at a concentration within the range of 1 μg/mL to 50 μg/mL.
[Aspect 14]
14. The method according to any one of embodiments 10 to 13, wherein saponin is combined with at least one transfection reagent selected from the group consisting of liposome-based transfection reagents and polymer-based transfection reagents. A method, characterized in that it is used in
[Aspect 15]
The saponin according to any one of aspects 1 to 3 is obtained from Agrostemma githago L. A method for isolating from
Agrostemma githago L. A step of pulverizing the seeds and defatting the pulverized seeds with an organic solvent to obtain defatted pulverized seeds;
freeze-drying the defatted pulverized seeds to obtain seed powder;
Extracting the seed powder with an alcohol solvent to obtain a seed extract;
removing the alcohol solvent from the seed extract to obtain a dry extract;
dissolving the dried extract in a low concentration organic solvent to obtain an extract solution;
subjecting the extract solution to at least one chromatographic separation step to obtain a purified saponin solution; and
removing the solvent from the purified saponin solution to obtain purified saponin powder;
including methods.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP19217512.3A EP3838910B1 (en) | 2019-12-18 | 2019-12-18 | Efficient gene delivery tool with a wide therapeutic margin |
EP19217512.3 | 2019-12-18 | ||
PCT/EP2020/086781 WO2021122998A1 (en) | 2019-12-18 | 2020-12-17 | Efficient gene delivery tool with a wide therapeutic margin |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2023507468A JP2023507468A (en) | 2023-02-22 |
JPWO2021122998A5 true JPWO2021122998A5 (en) | 2023-12-20 |
Family
ID=68944641
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2022537736A Pending JP2023507468A (en) | 2019-12-18 | 2020-12-17 | Efficient gene delivery tools with broad therapeutic limits |
Country Status (8)
Country | Link |
---|---|
US (1) | US20230039644A1 (en) |
EP (1) | EP3838910B1 (en) |
JP (1) | JP2023507468A (en) |
AU (1) | AU2020409687A1 (en) |
CA (1) | CA3160625A1 (en) |
ES (1) | ES2931037T3 (en) |
IL (1) | IL293923A (en) |
WO (1) | WO2021122998A1 (en) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2017281497B2 (en) | 2016-06-22 | 2023-04-06 | Proqr Therapeutics Ii B.V. | Single-stranded RNA-editing oligonucleotides |
WO2023152371A1 (en) | 2022-02-14 | 2023-08-17 | Proqr Therapeutics Ii B.V. | Guide oligonucleotides for nucleic acid editing in the treatment of hypercholesterolemia |
WO2024013361A1 (en) | 2022-07-15 | 2024-01-18 | Proqr Therapeutics Ii B.V. | Oligonucleotides for adar-mediated rna editing and use thereof |
WO2024013360A1 (en) | 2022-07-15 | 2024-01-18 | Proqr Therapeutics Ii B.V. | Chemically modified oligonucleotides for adar-mediated rna editing |
WO2024110565A1 (en) | 2022-11-24 | 2024-05-30 | Proqr Therapeutics Ii B.V. | Antisense oligonucleotides for the treatment of hereditary hfe-hemochromatosis |
GB202218090D0 (en) | 2022-12-01 | 2023-01-18 | Proqr Therapeutics Ii Bv | Antisense oligonucleotides for the treatment of aldehyde dehydrogenase 2 deficiency |
WO2024121373A1 (en) | 2022-12-09 | 2024-06-13 | Proqr Therapeutics Ii B.V. | Antisense oligonucleotides for the treatment of cardiovascular disease |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2955285T3 (en) | 2017-07-11 | 2023-11-29 | Univ Berlin Freie | New uses of a saponin and method for its isolation |
-
2019
- 2019-12-18 ES ES19217512T patent/ES2931037T3/en active Active
- 2019-12-18 EP EP19217512.3A patent/EP3838910B1/en active Active
-
2020
- 2020-12-17 AU AU2020409687A patent/AU2020409687A1/en active Pending
- 2020-12-17 CA CA3160625A patent/CA3160625A1/en active Pending
- 2020-12-17 US US17/787,296 patent/US20230039644A1/en active Pending
- 2020-12-17 IL IL293923A patent/IL293923A/en unknown
- 2020-12-17 WO PCT/EP2020/086781 patent/WO2021122998A1/en active Application Filing
- 2020-12-17 JP JP2022537736A patent/JP2023507468A/en active Pending
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RU2349337C2 (en) | Pharmaceutical composition including steroid saponins, method of obtainment, and application | |
JPH07504910A (en) | Novel aminosterol antibiotics | |
JPWO2021122998A5 (en) | ||
WO2000009137A2 (en) | Aminosterol compounds and uses thereof | |
WO2007009265A1 (en) | NOVEL β-CYCLODEXTRIN-BASED MOLECULES AND DRUG DELIVERY COMPOSITIONS | |
FR2691465A1 (en) | New melanotropin peptide(s) and polysaccharide conjugates - useful as antiinflammatory, antiallergic, immunosuppressant and skin-tanning agents | |
Göransson et al. | Cyclotides in the Violaceae | |
KR20120068898A (en) | Picrorhiza kurroa extract for prevention, elimination and treatment of rna viruses and infection or diseases caused by the same in humans, animals and in biotech industry | |
CN108912183B (en) | Catalpol derivative acylated with croton and preparation method and application thereof | |
Kawase et al. | Nucleic-acid and protein changes in blood and midgut of the silkworm, Bombyx mori (Linnaeus), during the course of cytoplasmic polyhedrosis | |
JPH0578384A (en) | Flavonol derivative | |
CN105777864B (en) | Pentacyclic triterpene-peptide conjugate, preparation method, pharmaceutical composition and application thereof | |
Wilke et al. | Cytotoxic lipidic α-amino acids from the zoanthid Protopalythoa variabilis from the northeastern coast of Brazil | |
JPH0317020A (en) | Anti-hiv agent | |
JP2013532759A (en) | Glycolipids for the treatment of ischemia reperfusion injury | |
CN111269284B (en) | Reagents and methods for simultaneous separation of proteins and RNAs in cytoplasm and nucleus | |
CA3040647A1 (en) | Novel resorcinarene-based amphipathic compound and use thereof | |
DE102004011988A1 (en) | Cyclosporin derivatives and pharmaceutical compositions containing them | |
JP4195089B2 (en) | Macrocyclic compounds produced from suboxide units | |
Chayrov et al. | Tailoring acyclovir prodrugs with enhanced antiviral activity: Rational design, synthesis, human plasma stability and in vitro evaluation | |
JP2631686B2 (en) | Novel steroid saponins, their production methods and novel uses of these derivatives | |
TWI618540B (en) | Composition for preventing renal toxicity caused by drug toxicity, preparation method thereof and Its use | |
JP5675034B2 (en) | Neutral lipid absorption inhibitor and saponin compound obtained from daisy and use thereof | |
WO2007066355B1 (en) | Processes for the preparation and estimation of enriched calcitriol containing extracts from cestrum diurnum and compositions thereof | |
CN1684680A (en) | Imidazole alkaloids from lepidium meyenii and methods of usage |